Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, TheHungryHippo, BluSkies, Rdy1, Ryguy008
Search This Board: 
Last Post: 6/23/2017 4:38:16 PM - Followers: 867 - Board type: Free - Posts Today: 181


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
#71576  Sticky Note QUOTE LOL, Hippo DD info found here! sdave2002 06/22/17 03:42:36 PM
#71477  Sticky Note Investors are getting back into USRM Ryguy008 06/22/17 10:44:47 AM
#70960  Sticky Note Quote LOL, "Well they have time to take Hornet Driver 06/20/17 01:59:15 PM
#70115  Sticky Note MyoCell therapy "$35,000 to $45,000 range" per patient TheHungryHippo 06/19/17 12:14:48 AM
#70057  Sticky Note CEO Blog: June is TheHungryHippo 06/18/17 10:57:39 PM
#71843   No... I honestly don't take others advice about trading. BoilerRoom 06/23/17 04:49:03 PM
#71842   Confirmation of a buy signal today Work Harder 06/23/17 04:45:43 PM
#71841   Why not receiving RMAT designation might be good 4toSchool 06/23/17 04:38:16 PM
#71840   LOL so you took my advice? Bought usrm Archery Class 06/23/17 04:38:00 PM
#71839   I am happy today, got out on red olley4863 06/23/17 04:07:04 PM
#71836   I'm not a financial advisor people buy and BoilerRoom 06/23/17 03:36:47 PM
#71834   what news do you expect after hours? Chicagojosh 06/23/17 03:33:59 PM
#71832   We can enjoy a few epic runs along Hippycowboy 06/23/17 03:25:30 PM
#71831   Don't worry I don't... Good luck BoilerRoom 06/23/17 03:23:15 PM
#71829   Buy low sell high go in big get BoilerRoom 06/23/17 03:21:05 PM
#71828   Reversal confirmed it seems :) Track 06/23/17 03:20:41 PM
#71827   Thanks man good luck looks great BoilerRoom 06/23/17 03:20:09 PM
#71826   HIPPYCOWBOY THAT IS THE RIGHT ATTITUDE !! power11 06/23/17 03:20:08 PM
#71825   Teach me make me rich rob911 06/23/17 03:20:04 PM
#71823   Glad you finally joined team MILLIONAIRE BRO TooYoungToDie 06/23/17 03:18:43 PM
#71822   USRM added more today all in... Going to BoilerRoom 06/23/17 03:15:25 PM
#71820   Wowzers What a Friday$$$$ TooYoungToDie 06/23/17 03:10:23 PM
#71819   Im here! Just chill'n and enjoying the ride! Hippycowboy 06/23/17 02:55:58 PM
#71818   May not take that long! Hold and wait sdave2002 06/23/17 02:50:50 PM
#71817   Please Read! Guys if we get past .59-.6 Ryguy008 06/23/17 02:46:57 PM
#71816   Its time man its time.... accesswire on a Ryguy008 06/23/17 02:44:33 PM
#71815   Very nice. Oshinko 06/23/17 02:44:30 PM
#71814   Should stay at 0.04 or higher this week... BoilerRoom 06/23/17 02:44:27 PM
#71813   I've been buying all week. Waited until it sdave2002 06/23/17 02:37:43 PM
#71812   2s and 3s Monday zturk 06/23/17 02:35:45 PM
#71811   Maybe so. They are doing great things with Hooey 06/23/17 02:35:43 PM
#71810   USRM moneymaker here BoilerRoom 06/23/17 02:33:07 PM
#71809   Just fooling around Dude. I know what I Hooey 06/23/17 02:31:54 PM
#71808   Better be through ACCESSWIRE!! haha caltr0m 06/23/17 02:31:24 PM
#71807   Big news after hours plus today action equals Ryguy008 06/23/17 02:30:44 PM
#71806   Let's take this puppy for a really long Hippycowboy 06/23/17 02:29:14 PM
#71805   Boom longs Ppl are realizing how dirt cheap this TooYoungToDie 06/23/17 02:29:12 PM
#71804   Don't sell short and don't cut us short. 7s docprep 06/23/17 02:28:42 PM
#71803   Hey, I'm 5-9 and they say stem cells zturk 06/23/17 02:27:54 PM
#71802   nice to see this headed back where it dirtydozen911 06/23/17 02:27:33 PM
#71801   HairCell by Howard Leonhardt: bow-tie 06/23/17 02:25:35 PM
#71800   Hell they probly cure ed too. Hooey 06/23/17 02:24:19 PM
#71799   im all for usrm, i hope they do penny k 06/23/17 02:24:12 PM
#71798   Someone wants shares.. Nice Bid support right here sdave2002 06/23/17 02:24:07 PM
#71797   $USRM Nickel-plus!! trading.jeff 06/23/17 02:22:45 PM
#71796   Hair loss too??? Geez...that's a pretty large profit sector docprep 06/23/17 02:22:18 PM
#71795   Make them pay for those shares. Break those .05's.... sdave2002 06/23/17 02:22:07 PM
#71794   Stem Cell treatment for hair loss also gaining steam... sdave2002 06/23/17 02:18:44 PM
#71793   Nice run davidegoh 06/23/17 02:18:15 PM
#71792   Easy does it. 5s today, 7s by zturk 06/23/17 02:16:20 PM
#71791   Agree! Hippycowboy 06/23/17 02:15:10 PM
#71790   I agree! Take half leave half works great Hippycowboy 06/23/17 02:13:27 PM
#71789   Not fantasy. While we all wish it didn't happen...Mondays docprep 06/23/17 02:10:54 PM
#71788   $$USRM$$ Weeeeeeeeeeee!!!! BoilerRoom 06/23/17 02:10:12 PM
#71787   Will be trading on Nasdaq in the next Tdogwm 06/23/17 02:05:17 PM